Background-Mutations in the LMNA gene, encoding lamins A/C, represent a significant cause of dilated cardiomyopathy.
T he lamins are a family of intermediate filament proteins, which localize to the inner nuclear envelope in which they perform a number of crucial functions involving nuclear architecture, gene expression, mitosis, DNA replication, apoptosis, and signaling (reviewed in references 1 and 2). The major A-type lamins, lamins A and C, are produced through differential splicing of the 12 exon LMNA gene (1q21. 2-q21.3) . Because the alternative splice site is located in exon 10, lamin A and C transcripts encode proteins that differ along only a short C-terminal segment. The N-termini represent a series of ␣-helical coiled-coil domains necessary for lamin polymerization. 3 The C-terminal tail domain, in contrast, adopts an immunoglobulin (Ig)-like structure and house-binding sites for DNA, chromatin, and other laminassociated polypeptides. 4 Together, these domains permit the array of interactions necessary for maintaining integrity of the lamina.
Clinical Perspective on p 14
Production of a mature lamin A polypeptide (664aa) necessitates a series of posttranslational modifications targeted to the prelamin A C-terminal CaaX motif, which is lacking in the truncated lamin C (572aa). Although the precise functions of prelamin A processing remain unknown, the sequential modifications may facilitate interactions with other lamina proteins or with the nuclear membrane. 5 LMNA mutations have been implicated in at least 8 distinct clinical phenotypes (laminopathies). Although recognized as unique entities, reports of patients 6 or families 7 exhibiting features of Ͼ1 disease and of individual mutations resulting in multiple laminopathies 8, 9 suggest that these diseases may be better considered as a phenotypic spectrum. Forms of muscular dystrophy with or without cardiac involvement (autosomal dominant Emery Dreifuss muscular dystrophy, limb-girdle muscular dystrophy type 1B), diseases of adipose tissue and fat deposition (familial partial lipodystrophy-Dunnigan type, mandibuloacral dysplasia), restrictive dermopathy, Charcot-Marie-Tooth disease type 2, and premature aging syndromes, such as Hutchinson-Gilford progeria syndrome and atypical Werner syndrome, are all part of the spectrum. LMNA mutations additionally represent the most frequent known genetic cause of dilated cardiomyopathy (DCM), occurring with a prevalence of Ϸ5% to 10% (familial) and 2% to 5% (sporadic). 10 Missense mutations predominate; however, rare deletions, insertions, frameshifts, and nonsense mutations have all been reported.
Clinically, LMNA-related DCM is characterized by much inter-and intrafamilial variability in onset and severity but typically manifests as left ventricular enlargement and reduced systolic function preceded by significant conduction system disease (CSD), particularly atrioventricular block and supraventricular arrhythmias. Sudden cardiac death is also common and can represent the initial sign of disease (see references 11 and 12 for review).
We recently identified 18 unique protein-altering LMNA variants in 19 probands from a cohort of 324 unrelated patients with idiopathic (nonischemic DCM of unknown cause) or familial DCM. 10 Identified variants showed usual patterns of age-dependent segregation with disease in many of the larger families (segregation pedigrees), supporting the pathogenicity of these mutations. However, the small sizes of other families precluded definitive assessments of segregation (unknown segregation pedigrees). We additionally observed that in 6 of the 19 families (32%), at least 1 family member with clinically evident DCM lacked the putatively causative LMNA variant (nonsegregation pedigrees), raising questions regarding the contribution of these variants to disease. 10 A large number of studies have demonstrated abnormalities in nuclear morphology and lamin A/C localization in cells expressing LMNA variants. [13] [14] [15] [16] [17] [18] [19] [20] [21] Therefore, to better determine their pathogenic potential, we generated GFP-prelamin A fusion constructs corresponding to 13 of the 18 identified LMNA variants (including variants lacking definitive segregation data) and constitutively expressed each in COS7 cells. These studies complement available molecular, family, and/or clinical data 10, 22, 23 by providing evidence supporting pathogenicity for 10 of the 13 analyzed LMNA variants.
Methods

Plasmid Construction
Full-length human prelamin A (664 amino acids) was generated from HEK293 total RNA extract using the Transcriptor High Fidelity cDNA Synthesis Kit (Roche Applied Science, Indianapolis, Ind.) and was cloned into the pAcGFP1-C1 fluorescent protein expression vector (Clontech, Mountain View, Calif.) using manufacturer's protocols for the In-Fusion 2.0 Dry-down Kit (Clontech). The In-Fusion Primer Design Tool (http://bioinfo.clontech.com/infusion/ convertPcrPrimersInit.do) was used to design sense (5Ј-GGACT-CAGATCTCGACTGCCGGCCATGGAGAC-3Ј) and antisense (5Ј-GATCCCGGGCCCGCGGCCTGGCAGGTCCCAGAT-3Ј) primers. Vector linearization was accomplished using Kpn1 and Xho1. The cloning reaction was performed with a vector:insert molar ratio of 1:2, and the resulting wild-type GFP-prelamin A fusion construct (GFPLaA-WT) was transformed into One Shot TOP10 Escherichia coli (Invitrogen, Carlsbad, Calif.). Construct fidelity was confirmed first by restriction analysis with BglII and BamHI and subsequently by dye-terminator sequencing using the ABI 3100 Automated Capillary DNA Sequencer (Applied Biosystems, Foster City, Calif.).
Mutagenesis
Thirteen mutant constructs were generated from GFPLaA-WT following manufacturer's protocols for the QuikChange II XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, Calif.). Mutations and their flanking sequences were confirmed as described earlier.
Constructs generated included the 6 variants in pedigrees with nonsegregation (R101P, A318T, R388H, R399C, S437Hfsx1, and R654X) and an additional 7 variants (R89L, R166P, R190Q, G203K, I210S, L215P, and R471H) representing all remaining missense variants in the cohort. To focus research efforts analyses were restricted to these 13 variants because the remaining 5 variants were considered likely to cause significant disruption of the LMNA gene (a splice site variant [35Ͼ-1GϾT] caused the loss of exon 2, 10 2 were nonsense mutations [R225X and Q234X], 1 was a frameshift mutation [E372RfsX107], and 1 was an insertion [G474.D175insE] mutation), and clinical data were consistent with their pathogenicity. 10
Cell Culture, Transfection, and Confocal Immunofluorescence Microscopy
COS7 (African green monkey kidney) cells were cultured in Dulbecco modified eagle's mediumϩGlutaMAX (Gibco, Carlsbad, Calif.) supplemented with 10% fetal bovine serum and 1% antibiotic/ antimycotic (Gibco) at 37°C in a 5% CO 2 water-jacketed incubator. The COS7 cell line was selected for its high transfectability and demonstrated utility in similar lamin A/C morphological studies. 21 Because WT lamin A overexpression has been shown to form aggregates similar to those observed in some mutant samples, 14, 17 transfection conditions were optimized to minimize aggregation of overexpressed GFP-lamin A in GFPLaA-WT samples before assessment of mutant constructs. Transfections were conducted using Lipofectamine 2000 reagent (Invitrogen) scaled for culture in 35-mm diameter, 10-mm microwell glass-bottom dishes (MatTek Corporation, Ashlord, Mass.). Twenty-four hours before transfection, 400 000 cells were seeded in growth medium lacking antibiotic and microcytic and were cultured overnight to 80% to 90% confluence. Plasmid DNA (0.5 g) was complexed with lipofectamine in a ratio of 1:2.5. Transfection proceeded for 24 hours at 37°C.
The same investigator (J.C.) completed all experiments. A second investigator (D.L.) assigned unique identifiers before transfection, blinding the first investigator to all sample identities. The first investigator remained blinded until all images were acquired, qualified, and analyzed.
Before image acquisition, overnight culture media was aspirated and replaced with 1-mL phenol red-free and antibiotic/antimycoticenriched Dulbecco modified eagle's medium and supplemented with 10 L Hoechst 33258 (0.2 mmol/L) nuclear stain. Images were acquired with a Zeiss LSM510/UV confocal microscope outfitted with a C-Apochromat 63x/1.2 W Corr water immersion objective lens and separate UV (351 nm) and GFP (488 nm) emission filters. During acquisition, fluorescent nuclei were qualitatively classified by observed nuclear morphology. Results of independent experiments were amalgamated for analysis. Postacquisition image processing was accomplished with AxioVision 4.7 software (Zeiss Microimaging Inc., Thormwood, N.Y.).
Statistical Analyses
The number of aggregate-containing and abnormally shaped nuclei for each variant LMNA construct were compared with corresponding WT counts using 2-tailed 2 (all cell counts Ͼ5) or Fisher exact tests (any cell count Յ5). InStat 3 (Graphpad Software, Inc., La Jolla, Calif.) statistical software (http://www.graphpad.com/) was used for all analyses.
Results
Clinical Data
Clinical and pedigree data from clinically affected individuals with confirmed or obligate LMNA mutations previously published by our group 10, 22, 23 are summarized for each family (Table 1, Figure 1 ).
Morphological Data
Full-length WT and mutant prelamin A cDNAs were transiently expressed as GFP fusion constructs in COS7 cells. Each construct was analyzed by confocal immunofluorescence microscopy to determine nuclear morphology and GFP-lamin A localization. The results are summarized (Tables 2 and 3) , and representative images are provided ( Figure 2 ).
Nearly all nuclei in cells transfected with GFPLaA-WT exhibited homogenous GFP-lamin A localization throughout the nuclear periphery (95%). Rarely, nuclei contained small, nuclear envelope-associated aggregates (5%). Transfection with the 13 mutant constructs resulted in a number of GFP-lamin A localization phenotypes. The GFPLaA-A318T (family L), -R399C (family O), and -R471H (family Q) constructs were morphologically comparable with GFPLaA-WT. A significantly greater proportion of nuclei with nuclear envelopeassociated aggregates was observed with GFPLaA-E203K (family G, 17%) and GFPLaA-R190Q (family F, 39%), although the majority of nuclei remained comparable with GFPLaA-WT. Even more severe phenotypes, characterized by Ͼ50% aggregation levels and unique GFP-lamin A distribution patterns, were seen with the remaining constructs. Of these, rates of aggregation were lowest for GFPLaA-L215P (family I, 64%) and significantly higher (Ͼ95%) for GFPLaA-R89L, -R101P, -R166P, and -I210S (families A, B, D/E, and H, respectively). GFPLaA-R388H (family N), GFPLaA-S437Hfsx1 (family P), and GFPLaA-R654X (family S) were most intriguing. GFPLaA-R388H was predominantly and markedly restricted to the cytoplasm, as a diffuse, low-fluorescence veil, or as highly saturated aggregates. Only rarely was nuclear localization observed, and in these few instances, GFP-lamin A was as likely to form small aggregates as to remain homogenously distributed. Equally unexpected was the finding of unique streaked aggregates (43%) in the nuclei of S437Hfsx1 expressing cells, and the presence of giant aggregates in S437Hfsx1 (50%) and R654X (5%) expressing nuclei. Smaller aggregates were also prominent.
Consistent with previous reports, 14 -16,19,20,25,26 all coil 1B variants exhibited variable levels of aggregation. Compared with cells expressing GFPLaA-WT, significantly higher levels of mild to gross nuclear shape abnormalities, including nuclear envelope blebbing, were additionally observed. The extent and relative severity of these abnormalities are summarized in Table 3 and Figure 2 . GFPLaA-R399C (family O) was uniquely notable for retraction of DNA from a clearly GFP-lamin A-demarcated nuclear lamina in rare transfected nuclei ( Figure 2 ). Although occurring in only a few cells, this phenotype was observed across multiple transfections and was considered to be an abnormal finding. Nevertheless, the majority of nuclei expressing GFPLaA-R399C, as well as all nuclei expressing GFPLaA-A318T (family L) and GFPLaA-R471H (family Q), were indistinguishable from WT. Abnormal nuclear phenotypes were ultimately observed for 10 of 13 (77%) LMNA constructs (Table 3) , including 4 of 6 (67%) incorporating variants from pedigrees with nonsegregation and 3 of 4 (75%) incorporating variants from pedigrees with uncertain segregation, collectively supporting pathogenicity of these variants.
Morphological data for 3 LMNA variants (A318T, R399C, and R471H) were less revealing, with each showing phenotypes comparable with WT, despite various associated manifestations of cardiovascular disease in carrier families. Families L (L.3) and Q (Q.2) exhibited severe CSD and/or DCM (Table 1 ). Two at-risk individuals in family Q (Q.4 and Q.5) additionally showed DCM/CSD of extremely early onset, with Q.5 notably suffering sudden cardiac death at 18 years of age. Conversely, no symptoms were present in the mutationpositive mother of the proband in family O (O.9), whereas a maternal grandfather (O.3), who also carried the R399C mutation, exhibited only CSD. Paternally inherited DCM/ CSD of unknown cause, however, was noteworthy, as was extremely aggressive, early onset DCM (requiring transplantation at 15 years) in the proband (O.11), who was also at risk of carrying a putative second, paternally inherited, causative genetic variant. These data suggest that the R399C variant may represent a low-risk allele acting in concert with an unknown paternal factor to cause the severe DCM of the proband. This mutation has been previously reported in a female patient with familial partial lipodystrophy-Dunnigan type 27 ; however, no evidence of DCM (or any other laminopathy) was present in that individual.
Discussion
To further delineate pathogenicity of LMNA variants previously identified in our DCM cohort, 10 we assessed nuclear morphology and GFP-lamin A localization in 13 variants. These included 6 variants in pedigrees, termed "nonsegregation" pedigrees, in which 1 or more family members with DCM did not carry the family variant, as well as 4 additional LMNA variants for which small family size (only 1 subject with DCM available for genetic analysis) precluded determination of segregation. These latter pedigrees were termed "pedigrees with unknown segregation." Of the 13 variants, 10 showed abnormal GFP-lamin A localization and/or nuclear morphological abnormalities. Considered alongside clinical diagnoses of CSD and/or DCM in mutation carriers, these data provide evidence for pathogenicity of 3 of the 4 variants identified in families with unknown segregation and 4 of the 6 variants identified in families with nonsegregation. The absence of the variants observed in the nonsegregation pedigrees in 150 unrelated controls or in LMNA mutation databases (http://www.dmd.nl and http://www.umd.be:2000/ IFAM.shtml), considered with the current morphological studies and prior molecular and pedigree data, 10 argues for the existence of a second, unidentified, causative factor in clinically affected, but LMNA mutation negative, family members. Whether these additional factors are genetically determined or environmentally imposed remains to be determined. However, the apparent heritable nature of DCM in some of the affected subjects who do not carry the LMNA variants (eg, pedigrees N, S) suggests that a second genetic cause of DCM may be present in these families. Collectively, these data suggest a more complex basis for DCM in some multiplex pedigrees than has been previously appreciated (see also Ref. 10).
As previously described for this cohort, 10 a number of mutation-positive individuals with no evidence of disease were present in several families (eg, pedigrees G, I, and N), showing age-dependent penetrance. Because LMNA-related DCM shows age-dependent penetrance (median, 40.9 years in Ref. 10) , this incomplete segregation is best explained by the relative youth of these individuals (23 to 41 years at the time of assessment) rather than nonpathogenicity of the familial variant. We distinguish these individuals who show incomplete, age-dependent segregation (a LMNA mutationpositive individual who has not yet manifested LMNA cardiomyopathy) from those subjects affected with DCM who do not carry the LMNA pedigree mutation, the latter of which are termed "nonsegregants" in this and the prior 10 work.
Because a number of previous studies have indicated that C-terminal mutations are significantly less likely to result in aggregation, 19, 20, 26 the lack of an abnormal R399C nuclear phenotype does not preclude pathogenicity of this variant, nor of the similarly expressed A318T (family L) and R471H (family Q) variants. C-terminal missense mutations resulting in lamin A aggregation 16, 17 have, nevertheless, been de-scribed. Caution is, consequently, necessary when considering results generated for these variants.
R388H, which borders the C-terminus of coil 2B and downstream nonhelical regions, was unique among the missense variants studied. Unexpectedly, expressing cells predominantly showed cytoplasmic GFP-lamin A localization and aggregation. The proximity of position 388 to the nuclear localization signal at 416 to 423 28 may offer some explanation for the dramatic localization defects; however, the fact that the R399C variant resulted in nuclear import indicates that at least a portion of the region proximal to the nuclear localization signal has no influence on this process. An alternative explanation is loss of stable association with critical binding partners, such as lamin-associated polypeptides, DNA, or chromatin. This hypothesis is consistent with the work of Strelkov et al, 29 which proposes that coil 2B is likely to interact with various lamin-binding partners. Demonstration that the nearby R377H mutation resulted in cytoplasmic localization of the lamin B receptor 30 supports this proposal, as do fluorescence loss of intensity after photobleaching experiments showing significantly increased mobility of R386K lamin A/C mutants. 13 We additionally report 2 severe GFP-lamin A distribution defects resulting from nonmissense genetic lesions. First, a novel C-terminal S437Hfsx1 insertion and frameshift unmasks a premature stop codon at position 438 leading to truncation of lamin A and lamin C by 227 and 135 amino acids, respectively. COS7 cells expressing this variant showed a variety of defects, often within the same nucleus. Although Ϸ35% of nuclei exhibited small membraneassociated aggregates similar to those observed for the coil1B variants, unique streaked aggregates (Ϸ43%) and giant aggregates (Ϸ50%) were also prominent. The streaked aggregates, which varied in size, shape, and number between nuclei, are a novel finding. Giant aggregates have been observed in cells expressing exogenous mutant lamin C, 13, 15 but have not, to our knowledge, been reported for lamin A. The second lesion, a R654X nonsense mutation, truncates prelamin A by 11 amino acids, removing the conserved CaaX motif and elongating the mature protein by 7 amino acids. This mutation was previously reported in a patient with Hutchinson-Gilford progeria syndrome and a homozygous null ZMPSTE24 mutation, 31 and, notably, the mother and brother of that individual both displayed no signs of laminopathy, despite carrying the nonsense mutation. This variant seemed to be pathogenic in our cohort (pedigree S), with carriers showing significant CSD and DCM, including instances of sudden cardiac death, pacemaker/implantable cardiac defibrillator placement, and heart failure. Ninety-five percent of expressing nuclei exhibited a variety of GFP-lamin A aggregates, including giant aggregates similar to those seen for S437Hfsx1(Ϸ5%).
Although our study did not address pathogenic mechanisms, we can hypothesize that loss of critical binding domains for DNA, chromatin, and lamin-associated polypeptides may have resulted in the abnormal S437Hfsx1 aggregate phenotypes. Furthermore, the inability of the truncated S437Hfsx1 and R654X transcripts to be posttranslationally modified may also have contributed to disease, possibly through failure to translocate to the nuclear envelope 5 and/or through accumulation of a toxic, incompletely processed precursor, as is seen in Hutchinson-Gilford progeria syndrome. 32 Two laminopathy pathogenicity models have been proposed, each attempting to recognize both the phenotypic breadth of the laminopathies and the web of interactions existing between the lamins, lamin-associated proteins, DNA, and chromatin. The "structural" model proposes that LMNA mutations increase cellular susceptibility to mechanical strain through impairment of interactions critical for nuclear and cytoskeletal stability. 33, 34 Because normal functioning places significant mechanical strain on individual muscle cells, the structural model has been particularly attractive for studying LMNA-related cardiomyopathy and muscular dystrophy. The alternative "gene-expression" model proposes that LMNA mutations impair critical signaling pathways through influence on gene expression at the nuclear periphery. This hypothesis is supported by abundant literature documenting heterochromatin loss or redistribution in patient fibroblasts for many of the laminopathies. [35] [36] [37] These 2 hypotheses are not necessarily mutually exclusive, in which capacities and to what extent abnormalities in nuclear architecture and/or gene expression determine particular laminopathic phenotypes are important questions and the subject of current experimentation.
Limitations
Although this in vitro heterologous cell system has been shown to be a useful and sensitive tool for determining the potential pathogenicity of novel LMNA variants in this and other research studies, [13] [14] [15] [16] [17] [18] [19] [20] [21] negative results for 3 variants carried by families with manifestations of cardiovascular disease suggest that more sophisticated approaches may reveal more subtle abnormalities. Additional nuclear morphological studies, gene transfer experiments into small animals, or studies with human pluripotent cells harboring LMNA variants may help to further clarify the potential impact of LMNA variants of uncertain pathogenicity.
Conclusions
LMNA mutations, a significant cause of genetic DCM, were assessed with nuclear morphology and GFP-lamin A localization studies. Analyses of the LMNA variants in nonsegregation pedigrees identified in our DCM cohort support pathogenicity of 4 of 6 and argue for the existence of a second, unidentified causative factor in these families. In addition, demonstration of abnormal GFPLaA localization in 3 of 4 pedigrees for which segregation is uncertain indicate that nuclear morphological studies may also be of value in cases in which LMNA-related DCM is suspected, but pedigree data are lacking.
